Skip to content

Immunovant, Inc. IMVT Debt-to-assets

Debt-to-assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
0.0×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
0.7×-0.4×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
0.0×
Summit Therapeutics logo
Summit TherapeuticsSMMT
0.0×
TG Therapeutics logo
TG TherapeuticsTGTX
0.5×+0.1×

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Calculated from Immunovant, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s debt-to-assets?
Immunovant, Inc. (IMVT) reported debt-to-assets of 0× in Q1 2026.
How has Immunovant, Inc.'s debt-to-assets changed year-over-year?
Immunovant, Inc.'s debt-to-assets decreased by 0.0% year-over-year, from 0× to 0×.
What is the long-term trend for Immunovant, Inc.'s debt-to-assets?
Over 5 years (2021 to 2026), Immunovant, Inc.'s debt-to-assets has grown at a -58.7% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.